# Eli Lilly & Co. will buy Kelonia Therapeutics for at least $3.25 billion.

*business · news · 2026-04-20 · The Boston Globe*

## Key points

- Eli Lilly will acquire Kelonia Therapeutics for $3.25 billion, with milestones increasing total up to $7 billion.
- Kelonia's KLN-1010 therapy genetically modifies immune cells inside the body for blood cancer treatment.
- This acquisition is Lilly's third Massachusetts biotech purchase in 2024, following Orna and Centessa deals.
- Lilly's recent partnerships and acquisitions focus on cell therapies that do not require cell removal.

**Companies:** Eli Lilly & Co., Kelonia Therapeutics, Orna Therapeutics, Centessa Pharmaceuticals, Nimbus Therapeutics, Repertoire Immune Medicines
**Countries:** United States

[Read the full story on The Boston Globe](https://www.bostonglobe.com/2026/04/20/business/eli-lilly-kelonia-acquisition-cancer/)

---

Canonical: https://newsio.io/n/5c4bc8d6-e2ee-41b9-8e8b-7693060ef986/eli-lilly-co-will-buy-kelonia-therapeutics-for-at-least-3-25-billion-the-acquisi
Summarized by Newsio from The Boston Globe. https://newsio.io/how-it-works